Specifically, the authors observed that because the earliest cognitive decline was detected by the memory composite in stage 1 of their staging process, “the SUVR threshold in Braak I/II ROI classifying stage 0 and stage 1 might be considered as the cutoff of tau biomarker to define Alzheimer’s disease” [12]. This evidence concerns the gene MAPT and Alzheimer disease.